Bioatla Inc (BCAB) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bioatla Inc   (NASDAQ: BCAB)


Bioatla Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Bioatla Inc's ROI in the second quarter of 2026?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Bioatla Inc 's return on investment (ROI) in its second quarter of 2026

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM - - -84.51 % -60.73 % -62 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -14 -15 -9 -2 11
Return On Investment (TTM) - - - - -254.17 %
BCAB's Overall Ranking # 4315 # 4244 # 3985 # 3615 #
Seq. Investment Change TTM - - -67.97 % -26.74 % -18.2 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -31 -51 -60 -65 -60

BCAB Company Profile >> Back to BCAB Roi Comparisons >> See Annual BCAB Return On Investment



Return On Investment BCAB's Ranking
Within: No.
Industry # 82
Sector # 537
Overall # 4315

Return On Investment Statistics
High Average Low
-37.67 %
-135.05 %
-516.74 %
(Mar 31 2021)   (Jun 30 2026)



  News about Bioatla Inc Return on Investment ROI

Advancements in Oncology Mecbotamab Vedotin (Mec-V) Shows Promising Survival Rates in Refractory Soft Tissue Sarcomas

November 7, 2025

Recent advancements in the field of oncology have introduced novel therapies aimed at improving survival outcomes for patients with refractory soft tissue sarcomas, a notoriously difficult-to-treat group of tumors. Among these, bio-therapeutic innovations such as Mecbotamab Vedotin (Mec-V), an antibody-drug conjugate (ADC) targeting the AXL receptor, have come to the forefront. Recent clinical findings suggest that Mec-V significantly enhances overall survival (OS) rates compared to existing treatment modalities.Soft tissue sarcomas encompass a diverse array of tumors that arise from connective tissues and often present treatment challenges, especially in advanced or refractory cases. Traditional therapies have yielded limited efficacy, with many patients facing poor prognoses. In light of such challenges, Mec-V, developed as an AXL-targeting ADC, offers a novel approach with promising outcomes.





Financial Statements
Bioatla Inc's II. Quarter Investments $ -14 Millions BCAB's Balance sheet
Bioatla Inc's II. Quarter Income $ 0 Millions Quarterly BCAB's Income Statement
BCAB's Income by Division See BCAB's Income by Division


BCAB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions -34 38 71 180 211
Y / Y Investment Growth - -46.4 % -60.81 % -14.46 % -
Net Income in Millions 60 -70 -123 -106 -95
Y / Y Net Income Growth - - - - -
Annual Return On Investment - -184.19 % -174.7 % -59.05 % -45.25 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BCAB's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BCAB's Competitors
Subscribers only: Roi for Bioatla Inc's Suppliers
Subscribers only: Return On Investment for BCAB's Customers

Other Ratios
BCAB's Roa BCAB's Inventory Turnover Ratio BCAB's Growth Rates BCAB's Dividend Statistics
BCAB's Profitability Ratios BCAB's Asset Turnover Ratio BCAB's Dividend Growth
BCAB's Roe BCAB's Valuation Ratios BCAB's Financial Strength Ratios BCAB's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Glucotrack Inc   843.28 %
Stablecoin Development Corporation  618.18 %
Omeros Corporation  198.34 %
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Arbutus Biopharma Corp  99.18 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %

Date modified: 2026-09-26T07:39:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.